# A Study of CLSP 5282 in HLA-A*03:01 Positive Adult Patients With Solid Tumors (SENTINEL-101)

Source: https://onco.cc/trials/nct07650357/  
OnCo record `nct07650357` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 1 trial of CLSP-5282 run by Clasp Therapeutics, Inc., not yet recruiting.

## Summary

A Study of CLSP 5282 in HLA-A*03:01 Positive Adult Patients With Solid Tumors (SENTINEL-101) is a phase 1 interventional study registered as NCT07650357 by Clasp Therapeutics, Inc., with 140 participants planned, started 2026-07. Conditions recorded: Advanced Solid Tumor, Non Small Cell Lung Cancer, Pancreatic Carcinoma and Colorectal Cancer. Interventions recorded: CLSP-5282.

## Fields

- Kind: Trial
- Status: planned
- Last checked: 2026-11-03
- Tags: pipeline; ctgov-ingest
- Registry id: NCT07650357
- Phase: 1
- Setting: SENTINEL-101: A Phase 1 Dose Escalation and Expansion Study of CLSP-5282 in HLA-A*03:01 Positive Adult Patients With Solid Tumors That Harbor the KRas G12V Mutation
- Sponsor: Clasp Therapeutics, Inc.
- Enrolled: 140

## Sources

- ClinicalTrials.gov NCT07650357: https://clinicaltrials.gov/study/NCT07650357

## Connected records

- cancers: [Colorectal cancer](https://onco.cc/cancers/colorectal/), [Metastatic cancer (cancer that has spread)](https://onco.cc/cancers/metastatic-cancer/), [Non-small-cell lung cancer](https://onco.cc/cancers/nsclc/), [Pancreatic ductal adenocarcinoma](https://onco.cc/cancers/pancreatic/)
- drugs: [CLSP-5282](https://onco.cc/drugs/clsp-5282/)
- companies: [Clasp Therapeutics](https://onco.cc/companies/clasp-therapeutics/)

---
JSON: https://onco.cc/api/v1/entities/nct07650357.json